Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
      • Scientific Advisory Board
    • Facilities
  • Therapeutic Areas
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long Covid
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Long COVID
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 ER
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-102 SL
      • TNX-1850
      • TNX-801
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix is enrolling participants in a Phase 3 trial for fibromyalgia, the RESILIENT study. For more information, please visit www.resilientstudy.com or www.clinicaltrials.gov (NCT05273749).

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Tonix in the News
    • Press Releases
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Tonix in the News
  • Press Releases
  • IR Events
  • Email Alerts
  • Op-Eds
Dec 12, 2017 7:00am EST

Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease

Nov 30, 2017 7:00am EST

Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference

Nov 7, 2017 7:00am EST

Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update

Nov 1, 2017 7:00am EDT

Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference

Oct 17, 2017 7:00am EDT

Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD

Oct 12, 2017 7:00am EDT

Tonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference

Sep 29, 2017 7:00am EDT

Tonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C.

Sep 14, 2017 4:05pm EDT

Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

Sep 14, 2017 7:00am EDT

Tonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors

Sep 6, 2017 7:00am EDT

Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Next Pagearrow_forward
rss_feed News RSS
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2022 Tonix Pharmaceuticals Holding Corp.